Genetic profiling could help tailor hormone therapy for prostate cancer after surgery

edited by Sadie Harley , reviewed by Andrew Zinin

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:

Add as preferred source Credit: Tima Miroshnichenko from Pexels A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic classifier to determine whether tumor biology could help identify patients most likely to benefit from hormone therapy.